Hydroxyapatite-Based Home Treatment for Dentin Sensitivity in Celiac Patients
Launched by UNIVERSITY OF PAVIA · Jul 5, 2025
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new home treatment to help reduce tooth sensitivity and improve enamel health in adults with celiac disease. People with celiac disease often have weaker tooth enamel and sensitive teeth, which can cause discomfort. The study will compare two groups: one using a special toothpaste containing hydroxyapatite (a mineral that helps repair teeth) twice a day, and the other using the same toothpaste plus a hydroxyapatite mousse applied once every evening. The researchers want to see if adding the mousse provides extra benefits in reducing sensitivity and strengthening the teeth over a 6-month period.
Adults aged 18 or older with diagnosed celiac disease, who have enamel problems, active tooth decay, and sensitive teeth, may be eligible to join. Participants will need to follow the treatment routine at home and attend check-ups at the start, then after 1 week, 1 month, 3 months, and 6 months. During these visits, dentists will check tooth sensitivity, plaque buildup, gum health, and signs of tooth decay using special tools and simple tests. The study has not started recruiting yet, but it aims to find out if this easy-to-use home treatment can help people with celiac disease protect their teeth and reduce discomfort.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults (≥18 years of age) with a confirmed diagnosis of celiac disease.
- • Presence of enamel defects (hypomineralization or demineralization).
- • Presence of active carious lesions.
- • Self-reported dentin hypersensitivity.
- • Willingness to comply with the study protocol and follow-up schedule.
- • Written informed consent provided.
- Exclusion Criteria:
- • Age below 18 years.
- • Absence of confirmed celiac disease.
- • Poor compliance or low motivation to participate in a 6-month study.
- • Ongoing treatment with products affecting enamel mineralization.
- • Pregnancy or breastfeeding.
- • Participation in another clinical trial within the previous 30 days.
About University Of Pavia
The University of Pavia, a prestigious institution renowned for its commitment to academic excellence and research innovation, serves as a prominent clinical trial sponsor. With a strong emphasis on advancing medical knowledge and improving patient care, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical research. Collaborating with leading healthcare professionals and institutions, the University of Pavia is dedicated to exploring novel therapeutic approaches and fostering the translation of scientific discoveries into clinical practice, ultimately aiming to enhance health outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pavia, Lombardy, Italy
Patients applied
Trial Officials
Andrea Scribante, Associate Professor
Principal Investigator
University of Pavia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported